Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Trial Details

NCT ID

NCT07165847

Phase

PHASE2

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Status

RECRUITING

Cancer Type

Gastric Cancer

Locations (sample)

• Chongqing, Other (Non U.s.), China

Key Eligibility Criteria

• The patients are able to understand and voluntarily sign the written informed consent, which must be signed prior to the implementation of the desi…
• The age at the time of signing the informed consent form (ICF) is ≥ 18 years old, both male and female.
• Histologically confirmed to have HER2-negative gastric or gastroesophageal junction adenocarcinoma (Siewert type II or Siewert type III with ≤2 cm …
• The patients are willing to provide fresh blood, feces, and tumor tissue for biomarker analysis, and the tissue samples provided are of sufficient …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.